XLO
Xilio Therapeutics, Inc.Healthcare·Biotechnology
$8.46
$51M market cap
Revenue
$26.3M
Free Cash Flow
$-25.0M
Rev Growth
+0.0%
FCF Margin
-94.9%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a
2-Year Price History
$8.25-43.9%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 12.7 | -13.8 | -14.1 | -9.5 | -22.3 | -22.9 | -0.6 | 150.3 | 6.6 | 163.5 | -102.3% | -- | -- |
| Act | 2025-Q4 | 13.7 | -11.5 | -11.8 | 10.4 | -2.0 | -2.1 | -0.1 | 137.5 | 7.0 | 83.6 | -257.1% | -- | -- |
Valuation & Metrics
Market Stats
Price$8.46
Market Cap$51M
Enterprise Value$-93M
P/S Ratio1.9x
P/FCF--
EV/FCF--
FCF Margin (TTM)-94.9%
FCF Yield-49.4%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$26.3M
Net Income$0.8M
Free Cash Flow$-25.0M
Revenue Growth (YoY)+0.0%
EBITDA Margin-96.0%
Net Margin3.2%
FCF Margin-94.9%
CapEx % of Revenue2.5%
SBC % of Revenue11.1%
ROIC-179.7%
WC Change % Rev11.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares0.2M
Days to Cover4.9
Change (vs Prior)-6.5%
Need at least 2 settlement dates for chart
Employees
Headcount64
Revenue / Employee$411,469
Gross Profit / Employee$406,094
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
29.1%
18 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
3.3%
5 filers
Vanguard, iShares, SPDR
Market makers
0.0%
0 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
Not enough quarterly ownership history to chart yet.
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | $5.6M | $8.41 | +$5.6M | +$5.6M | — | $1.11B |
| Frazier Life Sciences Management, L.P. | $3.6M | $8.41 | +$3.6M | +$3.6M | — | $3.89B |
| Sio Capital Management, LLC | $1.3M | $8.41 | +$1.3M | +$1.3M | — | $694M |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $1.0M | $8.41 | +$1.0M | +$1.0M | — | $4.04T |
| Caligan Partners LP | $943K | $8.41 | +$943K | +$943K | — | $1.41B |
| Merck & Co., Inc. | $891K | $8.41 | +$891K | +$891K | — | $349M |
| Stonepine Capital Management, LLC | $540K | $8.41 | +$540K | +$540K | — | $113M |
| MORGAN STANLEY | $484K | $8.41 | +$484K | +$484K | — | $1.65T |
| RENAISSANCE TECHNOLOGIES LLC | $417K | $8.41 | +$417K | +$417K | — | $63.91B |
| AJU IB Investment Co., Ltd. | $401K | $8.41 | +$401K | +$401K | — | $30.5M |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $313K | $8.41 | +$313K | +$313K | — | $1.61T |
| FMR LLC | $307K | $8.41 | +$307K | +$307K | — | $1.89T |
| VANGUARD FIDUCIARY TRUST COPassive | $239K | $8.41 | +$239K | +$239K | — | $395.83B |
| GSA CAPITAL PARTNERS LLP | $143K | $8.41 | +$143K | +$143K | — | $1.61B |
| Velan Capital Investment Management LP | $120K | $8.41 | +$120K | +$120K | — | $160M |
| Ghisallo Capital Management LLC | $116K | $8.41 | +$116K | +$116K | — | $2.56B |
| STATE STREET CORPPassive | $112K | $8.41 | +$112K | +$112K | — | $2.89T |
| CWM, LLC | $35K | $8.41 | +$35K | +$35K | — | $37.83B |
| UBS Group AG | $34K | $8.41 | +$34K | +$34K | — | $562.11B |
| JPMORGAN CHASE & CO | $2K | $8.41 | +$2K | +$2K | — | $1.47T |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+0.57%
avg per quarter
Holders (ex-self)
—
excl. this stock
Buyers (this Q)
+0.57%
23 buyers · $0.02B in
Sellers (this Q)
+0.00%
0 sellers · $0.00B out
alpha coverage: 92% of $ has a lifetime-alpha record
Holder behavior (holder profile)source: holder
On big dips (−10%+)
-1.4%
how holders react when this stock falls
On quiet Qs
-3.1%
−10% to +10% baseline
On rallies (+10%+)
-7.6%
how they react when this stock rises
Holders' portfolio flow this Q
+4.0%
inflows — adds are organic
Sellers' portfolio flow this Q
+0.0%
Sellers' overall flow ~ flat.
New buyers this quarter
Bain Capital Life Sciences Investors, LLC+$0.01BFrazier Life Sciences Management, L.P.+$0.00BSio Capital Management, LLC+$0.00BVANGUARD CAPITAL MANAGEMENT LLC+$0.00BCaligan Partners LP+$0.00BMerck & Co., Inc.+$0.00BStonepine Capital Management, LLC+$0.00BMORGAN STANLEY+$0.00BRENAISSANCE TECHNOLOGIES LLC+$0.00BAJU IB Investment Co., Ltd.+$0.00B
Top-5 holders · 74.9%
Bain Capital Life Sciences Investors, LLC--
Frazier Life Sciences Management, L.P.--
Sio Capital Management, LLC--
VANGUARD CAPITAL MANAGEMENT LLC--
Caligan Partners LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
Not enough holder history to plot.
Analyst Coverage
Analyst Coverage
Analyst Ratings
3
Buy: 3Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$117K
4 txns · 2 insiders · 111,289 sh
Sells ($, 12mo)
$6K
2 txns · 2 insiders · 8,856 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$30.01M
2 txns · 1 insider · 57,079,000 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-03-26 | BUY | Shannon James Samuel | director | 5,000 | $8.79 | $44K | $88K |
| 2026-02-13 | BUY | GILEAD SCIENCES, INC. | 10 percent owner | 3,739,000 | $0.00 | $374 | $4K |
| 2026-01-02 | SELL | Brennan Kevin M. | officer: SVP, FINANCE AND ACCOUNTING | 1,826 | $0.64 | $1K | $4K |
| 2026-01-02 | SELL | Frankenfield Christopher James | officer: Chief Financial Officer | 7,030 | $0.64 | $5K | $16K |
| 2025-06-17 | BUY | Shannon James Samuel | director | 25,000 | $0.69 | $17K | $48K |
| 2025-06-16 | BUY | Russo Rene | director, officer: PRESIDENT AND CEO | 36,289 | $0.68 | $25K | $191K |
| 2025-06-16 | BUY | Shannon James Samuel | director | 45,000 | $0.69 | $31K | $31K |
| 2025-06-05 | BUY | GILEAD SCIENCES, INC. | 10 percent owner | 53,340,000 | $0.56 | $30.01M | $13.11M |
Order Flow (FINRA, ~3w lag)
43.8%retail+2.7pp
15.5%dark-5.0pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Xilio Therapeutics: A Clinical-Stage Dilution Machine Navigating Negative Equity and Going Concern Warnings
Overall Risk
9/10
Fraud
3/10
Dilution
10/10
Insolvency
9/10
Earnings Overstated
5/10
Hidden Liabilities
6/10
Legal
3/10
Audit Warnings
10/10
Hidden Upside
6/10
Contextually Acceptable
2/10